ATE437637T1 - Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren - Google Patents

Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren

Info

Publication number: ATE437637T1
Authority: AT; Austria
Prior art keywords: nitric oxide; treating; pharmaceutically acceptable; acceptable salt; compositions
Prior art date: 2001-05-02

Application number

AT02766876T

Other languages

English (en)

Inventor

David Garvey

Original Assignee

Nitromed Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-02

Filing date

2002-05-01

Publication date

2009-08-15

2002-05-01 Application filed by Nitromed Inc filed Critical Nitromed Inc

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE437637T1 publication Critical patent/ATE437637T1/de

Links

KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
229960000619 nebivolol Drugs 0.000 title abstract 2
239000002207 metabolite Substances 0.000 title 1
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 7
208000024172 Cardiovascular disease Diseases 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 4
150000003839 salts Chemical class 0.000 abstract 3
239000003963 antioxidant agent Substances 0.000 abstract 2
230000003078 antioxidant effect Effects 0.000 abstract 2
239000002840 nitric oxide donor Substances 0.000 abstract 2
102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
208000003782 Raynaud disease Diseases 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000000066 endothelium dependent relaxing factor Substances 0.000 abstract 1
229960002474 hydralazine Drugs 0.000 abstract 1
-1 hydralazine compound Chemical class 0.000 abstract 1
RPTUSVTUFVMDQK-UHFFFAOYSA-N hydrallazine Natural products C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 abstract 1
229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 abstract 1
229960003827 isosorbide mononitrate Drugs 0.000 abstract 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Prostheses (AREA)

AT02766876T 2001-05-02 2002-05-01 Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren ATE437637T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28772501P	2001-05-02	2001-05-02
PCT/US2002/013667 WO2002087508A2 (en)	2001-05-02	2002-05-01	Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Publications (1)

Publication Number	Publication Date
ATE437637T1 true ATE437637T1 (de)	2009-08-15

Family

ID=23104065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02766876T ATE437637T1 (de)	2001-05-02	2002-05-01	Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren

Country Status (8)

Country	Link
US (2)	US7138430B2 (de)
EP (1)	EP1406608B1 (de)
JP (2)	JP2004528337A (de)
AT (1)	ATE437637T1 (de)
AU (1)	AU2002338528B2 (de)
CA (1)	CA2446064A1 (de)
DE (1)	DE60233140D1 (de)
WO (1)	WO2002087508A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10053397A1 (de)	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
CA2536173A1 (en) *	2003-08-20	2005-03-03	Nitromed, Inc.	Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP2264191A1 (de) *	2003-11-21	2010-12-22	ANP Technologies, Inc.	Asymmetrisch verzweigte Polymerkonjugate und Mikroarray-Tests
CA2554716A1 (en) *	2004-01-22	2005-08-04	Nitromed, Inc.	Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005102304A1 (en) *	2004-04-23	2005-11-03	Northern Sydney And Central Coast Area Health Service	Methods and compositions for the treatment of myocardial conditions
US7803838B2 (en) *	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US7838552B2 (en) *	2004-06-04	2010-11-23	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
JP4880591B2 (ja)	2004-06-04	2012-02-22	テバファーマシューティカルインダストリーズリミティド	イルベサルタンを含む医薬組成物
BRPI0513672A (pt)	2004-07-30	2008-05-13	Torrent Pharmaceuticals Limita	processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
US20080221203A1 (en) *	2004-08-09	2008-09-11	University Catholique De Louvain	Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease
SG175476A1 (en) *	2005-01-31	2011-11-28	Mylan Lab Inc	Glucuronidated nebivolol metabolites
WO2006083779A2 (en) *	2005-01-31	2006-08-10	Mylan Laboratories, Inc.	Pharmaceutical composition comprising hydroxylated nebivolol
US20060222592A1 (en) *	2005-04-05	2006-10-05	Clemens Burda	Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications
US8563329B2 (en)	2005-05-02	2013-10-22	Anp Technologies, Inc.	Polymer conjugate enhanced bioassays
RU2441653C2 (ru) *	2005-05-31	2012-02-10	Милан Лэборетериз, Инк.	Композиции, содержащие небиволол
NZ563759A (en) *	2005-05-31	2010-06-25	Mylan Lab Inc	Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
EP1943361A4 (de) *	2005-10-04	2009-04-15	Nitromed Inc	Genetische risikobeurteilung bei herzinsuffizienz: auswirkung der genetischen variation des aldosteronsynthase-promotor-polymorphismus
US20070154466A1 (en) *	2005-12-30	2007-07-05	Jan Weber	Internal medical devices containing peroxide-converting catalysts
US20080193385A1 (en) *	2007-02-08	2008-08-14	Todd Maibach	Compositions and methods for treating neuropathy
CA2599082A1 (en) *	2007-08-27	2009-02-27	Ping I. Lee	Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds
WO2009026697A1 (en) *	2007-08-28	2009-03-05	University Of Manitoba	A method of reducing a vasodilatory response using a guanylate cyclase pathway inhibitor or an h2o2 reducing agent
EP2207570A2 (de)	2007-09-14	2010-07-21	Nitto Denko Corporation	Arzneimittelträger
US8946284B2 (en)	2008-08-01	2015-02-03	Arca Biopharma, Inc.	Methods and compositions involving (S)-bucindolol
HUP0800498A2 (en) *	2008-08-06	2010-03-29	Semmelweis Egyetem	Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
US8579964B2 (en)	2010-05-05	2013-11-12	Neovasc Inc.	Transcatheter mitral valve prosthesis
US11207109B2 (en)	2010-10-20	2021-12-28	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US9554897B2 (en)	2011-04-28	2017-01-31	Neovasc Tiara Inc.	Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en)	2011-04-28	2016-04-12	Neovasc Tiara Inc.	Sequentially deployed transcatheter mitral valve prosthesis
CN102977068A (zh) *	2012-05-03	2013-03-20	中国药科大学	一氧化氮供体型异色满酮类衍生物、其制备方法及用途
US9345573B2 (en)	2012-05-30	2016-05-24	Neovasc Tiara Inc.	Methods and apparatus for loading a prosthesis onto a delivery system
EP2946213B1 (de) *	2013-01-18	2023-05-24	synlab Services GmbH	Vorhersage des fortschreitens einer nierenerkrankung unter verwendung von homoarginin als biomarker
US9572665B2 (en)	2013-04-04	2017-02-21	Neovasc Tiara Inc.	Methods and apparatus for delivering a prosthetic valve to a beating heart
CN113069242A (zh)	2015-12-15	2021-07-06	内奥瓦斯克迪亚拉公司	经中隔递送系统
JP7006940B2 (ja)	2016-01-29	2022-01-24	ニオバスクティアラインコーポレイテッド	流出の閉塞を回避するための人工弁
US11173235B2 (en)	2016-07-15	2021-11-16	Cook Regentec Llc	Nitrite eluting devices and methods of use thereof
US11096781B2 (en)	2016-08-01	2021-08-24	Edwards Lifesciences Corporation	Prosthetic heart valve
US11602555B2 (en)	2016-11-17	2023-03-14	Renovion, Inc.	Treatment of respiratory tract diseases and infections with ascorbic acid compositions
US20180140419A1 (en)	2016-11-21	2018-05-24	Neovasc Tiara Inc.	Methods and systems for rapid retraction of a transcatheter heart valve delivery system
CA3073834A1 (en)	2017-08-25	2019-02-28	Neovasc Tiara Inc.	Sequentially deployed transcatheter mitral valve prosthesis
EP4473976A3 (de)	2017-11-17	2025-03-12	Renovion, Inc.	Stabile ascorbinsäurezusammensetzungen und verfahren zu ihrer verwendung
EP3768378B1 (de)	2018-03-22	2025-08-06	InCarda Therapeutics, Inc.	Neuartiges verfahren zur verlangsamung der ventrikulären rate
JP7018544B2 (ja)	2018-05-25	2022-02-10	アルカバイオファーマ，インコーポレイテッド	心房細動の処置のためのブシンドロールを伴う方法および組成物
EP3876870B1 (de)	2018-11-08	2023-12-20	Neovasc Tiara Inc.	Ventrikuläres einsetzen einer transkathetermitralklappenprothese
AU2020233892A1 (en)	2019-03-08	2021-11-04	Neovasc Tiara Inc.	Retrievable prosthesis delivery system
AU2020256195B2 (en)	2019-04-01	2022-10-13	Neovasc Tiara Inc.	Controllably deployable prosthetic valve
CN113924065B (zh)	2019-04-10	2026-01-30	内奥瓦斯克迪亚拉公司	具有自然血流的假体瓣膜
US11779742B2 (en)	2019-05-20	2023-10-10	Neovasc Tiara Inc.	Introducer with hemostasis mechanism
US11311376B2 (en)	2019-06-20	2022-04-26	Neovase Tiara Inc.	Low profile prosthetic mitral valve
EP4199863B1 (de)	2020-08-24	2024-05-29	Edwards Lifesciences Corporation	Systeme zur ausrichtung eines kommissurs einer herzklappenprothese mit einem kommissur einer natürlichen herzklappe
WO2022198259A1 (en) *	2021-03-25	2022-09-29	The Heart Research Institute Ltd	Treatment methods for pulmonary arterial hypertension
MX2024008001A (es)	2022-01-04	2024-07-12	Renovion Inc	Solucion acuosa que comprende una sal de glutation.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US311175A (en)		1885-01-27		And joseph l
CA1337429C (en)	1983-12-05	1995-10-24	Guy Rosalia Eugene Van Lommen	Derivatives of 2,2'-iminobisethanol
US4654362A (en) *	1983-12-05	1987-03-31	Janssen Pharmaceutica, N.V.	Derivatives of 2,2'-iminobisethanol
US4868179A (en)	1987-04-22	1989-09-19	Cohn Jay N	Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
CA1337432C (en)	1988-03-23	1995-10-24	Raymond M. Xhonneux	Method of lowering the blood pressure
US5428061A (en)	1988-09-15	1995-06-27	Schwarz Pharma Ag	Organic nitrates and method for their preparation
US5284872A (en)	1989-09-12	1994-02-08	Schwarz Pharma Ag	Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5380758A (en)	1991-03-29	1995-01-10	Brigham And Women's Hospital	S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
AU3071592A (en)	1991-11-14	1993-06-15	Brigham And Women's Hospital	Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
US5650447A (en)	1992-08-24	1997-07-22	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Nitric oxide-releasing polymers to treat restenosis and related disorders
US5910316A (en)	1992-08-24	1999-06-08	The United States Of America, As Represented By The Department Of Health And Human Services	Use of nitric oxide-releasing agents to treat impotency
DE4321306A1 (de)	1993-06-26	1995-01-05	Sanol Arznei Schwarz Gmbh	Disulfide
TW355683B (en)	1994-02-17	1999-04-11	Janssen Pharmaceutica Nv	Composition containing micronized nebivolol
PT801564E (pt) *	1994-12-28	2002-09-30	Janssen Pharmaceutica Nv	Utilizacao de nebivolol como agente anti-aterogernico
US5703073A (en)	1995-04-19	1997-12-30	Nitromed, Inc.	Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5932538A (en)	1996-02-02	1999-08-03	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5807847A (en)	1996-06-04	1998-09-15	Queen's University At Kingston	Nitrate esters
US6310052B1 (en)	1996-06-04	2001-10-30	Queen's University At Kingston	Nitrate esters and their use for neurological conditions
JP2001504457A (ja)	1996-11-01	2001-04-03	ニトロメドインコーポレーテッド	ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
IT1295694B1 (it)	1996-11-14	1999-05-27	Nicox Sa	Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it)	1997-06-27	1999-02-08	Nicox Sa	Sali nitrati di ace-inibitori
JP4856295B2 (ja)	1997-07-03	2012-01-18	アメリカ合衆国政府	新規な一酸化窒素放出アミジン誘導ジアゼニウムジオレート及びその組成物
IT1301759B1 (it)	1998-06-19	2000-07-07	Nicox Sa	Sali nitrati di farmaci antiipertensivi
WO2000049993A2 (en)	1999-02-24	2000-08-31	Nitromed, Inc.	Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
AU3713600A (en)	1999-03-01	2000-09-21	Nitromed, Inc.	Nitrosated and nitrosylated prostaglandins, compositions and metods of use
IT1308633B1 (it)	1999-03-02	2002-01-09	Nicox Sa	Nitrossiderivati.
IT1311923B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311924B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311921B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
WO2000067754A1 (en)	1999-05-12	2000-11-16	Nitromed, Inc.	Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
IT1314184B1 (it) *	1999-08-12	2002-12-06	Nicox Sa	Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AU780261B2 (en) *	1999-10-29	2005-03-10	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
IT1320176B1 (it)	2000-12-22	2003-11-26	Nicox Sa	Dispersioni solide di principi attivi nitrati.
AP2006003622A0 (en)	2003-12-02	2006-06-30	Nicox Sa	Nitrooxyderivatives of antihypertensive drugs
AU2004294297A1 (en)	2003-12-02	2005-06-16	Nicox S.A.	Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive drugs

2002
- 2002-05-01 AT AT02766876T patent/ATE437637T1/de not_active IP Right Cessation
- 2002-05-01 JP JP2002584860A patent/JP2004528337A/ja not_active Withdrawn
- 2002-05-01 CA CA002446064A patent/CA2446064A1/en not_active Abandoned
- 2002-05-01 EP EP02766876A patent/EP1406608B1/de not_active Expired - Lifetime
- 2002-05-01 DE DE60233140T patent/DE60233140D1/de not_active Expired - Lifetime
- 2002-05-01 WO PCT/US2002/013667 patent/WO2002087508A2/en not_active Ceased
- 2002-05-01 AU AU2002338528A patent/AU2002338528B2/en not_active Ceased
2003
- 2003-10-29 US US10/695,644 patent/US7138430B2/en not_active Expired - Fee Related
2005
- 2005-07-13 US US11/135,418 patent/US7384976B2/en not_active Expired - Fee Related
2010
- 2010-06-25 JP JP2010145153A patent/JP2010248226A/ja active Pending

Also Published As

Publication number	Publication date
US20040132805A1 (en)	2004-07-08
DE60233140D1 (de)	2009-09-10
EP1406608A4 (de)	2004-10-20
US7384976B2 (en)	2008-06-10
CA2446064A1 (en)	2002-11-07
US7138430B2 (en)	2006-11-21
US20060009513A1 (en)	2006-01-12
JP2004528337A (ja)	2004-09-16
AU2002338528B2 (en)	2008-01-24
EP1406608B1 (de)	2009-07-29
WO2002087508A2 (en)	2002-11-07
EP1406608A2 (de)	2004-04-14
WO2002087508A3 (en)	2003-12-11
JP2010248226A (ja)	2010-11-04

Legal Events

Date	Code	Title	Description
2010-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE437637T1 (de)	2009-08-15	Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
EA200600317A1 (ru)	2006-06-30	Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
DE60327745D1 (de)	2009-07-09	Verwendung von adapalen zur behandlung dermatologischer erkrankungen
EP2325651A3 (de)	2011-09-21	Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
UA84420C2 (ru)	2008-10-27	СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК
BR0209127A (pt)	2006-03-21	compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0412659A (pt)	2006-09-26	isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
NO20055219L (no)	2006-01-04	Nye forbindelser
ECSP055525A (es)	2005-03-10	Inhibidores de cinasas de tirosina
SE9800836D0 (sv)	1998-03-13	New Compounds
DE602005025517D1 (de)	2011-02-03	Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
DE60324544D1 (de)	2008-12-18	Muskarin antagonisten
BR0318278A (pt)	2006-05-23	compostos de éter aminocicloexìlico e usos dos mesmo
WO2004012659A3 (en)	2004-10-07	Nitrosated proton pump inhibitors, compositions and methods of use
EE200400031A (et)	2004-04-15	Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
BR0209128A (pt)	2005-11-01	Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
CY1108224T1 (el)	2014-02-12	Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα
NO995431L (no)	1999-11-05	Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
DK1532131T3 (da)	2009-02-09	Motilid-forbindelser
WO2004002420A3 (en)	2004-07-01	Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
WO2004012686A3 (en)	2004-07-29	Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
MXPA06003345A (es)	2006-06-08	Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
BR0312183A (pt)	2005-04-05	Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica
DE60103034D1 (de)	2004-06-03	Neue phenylheteroalkylamin-derivate
SE0102641D0 (sv)	2001-07-31	Novel compounds